Karin Baughman
Psychiatric/Mental Health · Springfield, MONPI 1811340268
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,336 of the $15,876 with a category attached, or 77.7%. Teva Pharmaceuticals USA, Inc. accounts for 84.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $7,030 and has fallen 65.3% since, to $2,439 in 2025. Among psychiatric/mental health clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 47 payments — averaging $337.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$13K
- Alkermes, Inc.$537
- Axsome Therapeutics, Inc.$406
- Johnson & Johnson$383
- AbbVie$347
- Neurocrine Biosciences, Inc.$210
- plus $571 from 5 others
What the payments were for
- Speaking & faculty fees$12,33678%
- Travel & lodging$3852%
- Food & beverage$3,12820%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 21 | $13,421 |
| Alkermes, Inc. | 5 | $537 |
| Axsome Therapeutics, Inc. | 4 | $406 |
| Johnson & Johnson | 4 | $383 |
| AbbVie | 5 | $347 |
| Neurocrine Biosciences, Inc. | 2 | $210 |
| E.r. Squibb & Sons, L.L.C. | 2 | $146 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $120 |
| Sanofi | 1 | $110 |
| Eisai Inc. | 1 | $100 |
| Bayer | 1 | $95 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$12,903
- LYBALVI$943
- ARISTADA$480
- SPRAVATO$218
- Auvelity$214
- INGREZZA$123
- VRAYLAR$122
- CAPLYTA$120
- ARISTADA INITIO$120
- AUSTEDO$119
- FABRAZYME$110
- INVEGA SUSTENNA$108
- INVEGA TRINZA$108
- Austedo XR$108
- Dayvigo$100
How this compares
$15,876 in reported general payments places this provider in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 76 | $642,831 |
| VraylarCariprazine Hcl | 201 | $308,792 |
| AustedoDeutetrabenazine | 29 | $269,235 |
| Invega SustennaPaliperidone Palmitate | 71 | $236,086 |
| Austedo XrDeutetrabenazine | 23 | $136,712 |
| TrintellixVortioxetine Hydrobromide | 121 | $63,659 |
| RexultiBrexpiprazole | 32 | $49,124 |
| Abilify MaintenaAripiprazole | 16 | $47,004 |
| AristadaAripiprazole Lauroxil | 15 | $44,467 |
| Lurasidone Hcl | 271 | $42,624 |
| CaplytaLumateperone Tosylate | 24 | $37,445 |
| NuedextaDextromethorphan Hbr/Quinidine | 14 | $24,065 |
| AuvelityDextromethorphan Hbr/Bupropion | 20 | $21,950 |
| Paliperidone ErPaliperidone | 111 | $12,422 |
| BelsomraSuvorexant | 26 | $11,444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $210 | $642,83176 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $13,421 | $405,94652 claims |
| AbbVieVraylar | $347 | $308,792201 claims |
| Johnson & JohnsonInvega Sustenna | $383 | $236,08671 claims |
| Alkermes, Inc.Aristada | $537 | $44,46715 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $120 | $37,44524 claims |
| Axsome Therapeutics, Inc.Auvelity | $406 | $21,95020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Springfield
- Erin DuvallSpringfield$275K
- Emily WoukSpringfield$90K
- Tedra EstisSpringfield$13K
- Brian SmithSpringfield$10K
- Ashlee RossnerSpringfield$8K
- Holly JulianSpringfield$6K
- Kendra RasmussenSpringfield$6K
- Aldijana SacicSaint Louis$510K
- Laurel OwensLees Summit$246K
- Julie WaterburySaint Louis$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.